Bank of Montreal Can Has $482.83 Million Position in Pfizer Inc. (NYSE:PFE)

Bank of Montreal Can raised its position in Pfizer Inc. (NYSE:PFE) by 14.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 12,214,320 shares of the biopharmaceutical company’s stock after acquiring an additional 1,579,179 shares during the quarter. Bank of Montreal Can’s holdings in Pfizer were worth $482,831,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of PFE. Ameriprise Financial Inc. lifted its stake in shares of Pfizer by 111.3% during the 1st quarter. Ameriprise Financial Inc. now owns 17,940,336 shares of the biopharmaceutical company’s stock worth $649,995,000 after buying an additional 9,451,863 shares during the last quarter. Canada Pension Plan Investment Board lifted its stake in shares of Pfizer by 125.2% during the 1st quarter. Canada Pension Plan Investment Board now owns 13,765,773 shares of the biopharmaceutical company’s stock worth $498,734,000 after buying an additional 7,654,145 shares during the last quarter. Franklin Resources Inc. increased its position in Pfizer by 39.6% during the first quarter. Franklin Resources Inc. now owns 26,553,208 shares of the biopharmaceutical company’s stock worth $962,030,000 after acquiring an additional 7,532,823 shares during the period. Amundi Asset Management US Inc. increased its position in Pfizer by 41.5% during the first quarter. Amundi Asset Management US Inc. now owns 14,037,210 shares of the biopharmaceutical company’s stock worth $508,569,000 after acquiring an additional 4,114,833 shares during the period. Finally, Geode Capital Management LLC increased its position in Pfizer by 4.1% during the first quarter. Geode Capital Management LLC now owns 94,148,117 shares of the biopharmaceutical company’s stock worth $3,402,339,000 after acquiring an additional 3,699,308 shares during the period. Institutional investors own 64.93% of the company’s stock.

In other Pfizer news, SVP Jennifer B. Damico sold 2,500 shares of the company’s stock in a transaction dated Friday, July 30th. The shares were sold at an average price of $42.86, for a total transaction of $107,150.00. Following the sale, the senior vice president now directly owns 11,430 shares of the company’s stock, valued at $489,889.80. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Jennifer B. Damico sold 1,661 shares of the company’s stock in a transaction dated Friday, August 13th. The shares were sold at an average price of $48.30, for a total transaction of $80,226.30. The disclosure for this sale can be found here. 0.05% of the stock is currently owned by insiders.

A number of equities analysts recently commented on PFE shares. Berenberg Bank reaffirmed a “neutral” rating and set a $43.00 price target on shares of Pfizer in a research report on Tuesday, June 15th. JPMorgan Chase & Co. raised their target price on shares of Pfizer from $40.00 to $42.00 and gave the company a “neutral” rating in a report on Monday, September 13th. Royal Bank of Canada set a $44.00 target price on shares of Pfizer in a report on Thursday, July 29th. SVB Leerink raised their target price on shares of Pfizer from $49.00 to $50.00 and gave the company a “market perform” rating in a report on Monday, September 20th. Finally, The Goldman Sachs Group set a $48.00 target price on shares of Pfizer in a report on Thursday, July 29th. Eleven equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $42.85.

Shares of PFE stock opened at $43.76 on Monday. The firm has a market capitalization of $245.35 billion, a PE ratio of 18.86, a price-to-earnings-growth ratio of 1.58 and a beta of 0.74. The firm has a fifty day simple moving average of $45.45 and a two-hundred day simple moving average of $40.91. The company has a current ratio of 1.37, a quick ratio of 1.12 and a debt-to-equity ratio of 0.50. Pfizer Inc. has a 12 month low of $33.36 and a 12 month high of $51.86.

Pfizer (NYSE:PFE) last posted its earnings results on Wednesday, July 28th. The biopharmaceutical company reported $1.07 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.97 by $0.10. Pfizer had a net margin of 23.06% and a return on equity of 26.49%. The firm had revenue of $18.98 billion during the quarter, compared to analyst estimates of $17.54 billion. During the same quarter in the prior year, the business posted $0.78 EPS. On average, equities analysts predict that Pfizer Inc. will post 4.12 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Monday, December 6th. Investors of record on Friday, November 5th will be issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 3.56%. The ex-dividend date is Thursday, November 4th. Pfizer’s dividend payout ratio (DPR) is currently 70.27%.

Pfizer Company Profile

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Further Reading: How does the Beige Book influence monetary policy?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.